Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Ex-vivo Clonally Expanded B Lymphocytes Infiltrating Colorectal Carcinoma Are of Mature Immunophenotype and Produce Functional IgG

  • Claudia Maletzki ,

    Contributed equally to this work with: Claudia Maletzki, Annika Jahnke

    Affiliation Division of Molecular Oncology and Immunotherapy, Department of General Surgery, University of Rostock, Rostock, Germany

  • Annika Jahnke ,

    Contributed equally to this work with: Claudia Maletzki, Annika Jahnke

    Affiliation Division of Molecular Oncology and Immunotherapy, Department of General Surgery, University of Rostock, Rostock, Germany

  • Christiane Ostwald,

    Affiliation Institute of Pathology, University of Rostock, Rostock, Germany

  • Ernst Klar,

    Affiliation Division of Molecular Oncology and Immunotherapy, Department of General Surgery, University of Rostock, Rostock, Germany

  • Friedrich Prall,

    Affiliation Institute of Pathology, University of Rostock, Rostock, Germany

  • Michael Linnebacher

    michael.linnebacher@med.uni-rostock.de

    Affiliation Division of Molecular Oncology and Immunotherapy, Department of General Surgery, University of Rostock, Rostock, Germany

Ex-vivo Clonally Expanded B Lymphocytes Infiltrating Colorectal Carcinoma Are of Mature Immunophenotype and Produce Functional IgG

  • Claudia Maletzki, 
  • Annika Jahnke, 
  • Christiane Ostwald, 
  • Ernst Klar, 
  • Friedrich Prall, 
  • Michael Linnebacher
PLOS
x

Abstract

Background

Tumor infiltrating B cells (TiBc) have not yet been investigated in detail. This may at least in part be due to technical difficulties. Here we describe a straightforward and reproducible method to isolate and culture TiBc from primary colorectal carcinomas (CRC).

Methods/Results

TiBc cultures were generated by Epstein-Barr virus (EBV) immortalization. With this method, monoclonal TiBc cultures were obtained for 14/19 CRCs. As assessed by flow cytometry and ELISA, TiBc showed an activated immunophenotype (CD23+, CD80+) and produced immunoglobulin (Ig; IgG secretion in 55% of the cultures). In functional in vitro analysis, most of the IgGs specifically bound to allogeneic CRC target cells. These data suggest that TiBc are antigen-experienced and thus may exhibit functionality in situ. Additionally, mini-cultures generated from 12 further CRCs revealed TiBc outgrowth exclusively in the presence of EBV.

Conclusion

In summary, this simple method provides a cellular tool and our data set the stage for analysing the bivalent role of TiBc; being antigen-presenting cells on the one hand and tumor-specific antibody producers on the other. Additionally, the generation of long-term TiBc cultures and their monoclonal Ig may serve to identify novel tumor-specific antigens.

Introduction

Lymphocytes are major components of mononuclear cells infiltrating human malignant tumors. Their positive prognostic relevance is well established [1][3]. Recent studies focused on T cells, for they are believed to have the greatest antitumoral potential [4]. Indeed, a dense infiltrate of CD8+ cells was shown to correlate with prolonged survival of colorectal carcinoma (CRC) patients [5], [6].

However, tumor-infiltrating B cells (TiBc) may play an important role, too. They are considered to be positive regulators of immunity often collaborating with T cells to generate potent, unrelenting immune responses [7]. Beside their antibody (Ab) producing capacity, they enhance T cell responses by secreting stimulatory cytokines and chemokines, or by serving as local antigen-presenting cells (APCs).

The tumor entity in which most efforts have been undertaken in this regard is breast cancer. There, TiBc are present in about 24% of tumors and comprise up to 40% of lymphocytic infiltrates [8], [9]. They have been shown to undergo antigen-driven clonal proliferation and affinity maturation in situ [10]. Very recently, in a large patient cohort of different histological and biological subtypes, Mahmoud and colleagues provided evidence for a favorable outcome when high numbers of CD20+ TiBc are present. Of note, this prognostic value was independent from any clinicopathological marker [11]. So far, very few studies assessed the functional relevance of TiBc and the antibodies produced thereof. Using recombinant Ab cloning techniques, Hansen et al. reported an antigen-driven humoral immune response directed against β-actin exposed on apoptotic mammary carcinoma cells [12]. Following engraftment of lung cancer tissue in immunodeficient mice, Yasuda and co-workers identified TiBc producing tumor specific Abs against mutated p53 [13]. Thus, at least a proportion of TiBc accumulating in solid tumors can produce tumor antigen specific antibodies. TiBc could consequently be helpful for the identification of novel or at least of relevant tumor specific antigens (TSA).

Despite the obvious importance of B cells in immunological circuits, the functional role of TiBc was so far not examined in detail. This may be attributable to the difficulties in obtaining sufficient cell numbers, either by fresh isolation or by long-term culture. To overcome this obstacle, we designed a direct and reproducible method to generate immortalized B cell lines from primary tumor tissues. We used EBV-transformation by culturing B cells in the presence of virus-containing supernatant of the marmoset cell line B95/8 [14]. Clonality of outgrowing TiBc cultures, isotypes and function of secreted immunoglobulins (Ig) were analyzed.

Materials and Methods

Tumor specimens

Resection specimens of primary CRC without prior chemo- or radiotherapy (n = 19) were received fresh from surgery. Prior written informed consent was obtained from all patients, and all procedures were approved by the Ethics Committee of the University of Rostock (reference number II HV 43/2004) in accordance with generally accepted guidelines for the use of human material.

Molecular classification was done according to [15]. These data as well as staging information compiled from the clinical charts are summarized in Table 1.

thumbnail
Table 1. Data of colorectal carcinomas used for generation of TiBc bulk cultures, flow cytometry of CD19+CD20+ B cells from primary tumors and overall results of outcomes.

https://doi.org/10.1371/journal.pone.0032639.t001

Tumor cell lines and culture media

CRC cell lines HROC24 (MSI, Kraswt, Brafmut) and HROC46 (MSS, APCmut, Krasmut, Brafwt), were established in our lab from resection specimen [16]; HCT116 cells were originally obtained from ATCC, Rockville, MD, USA. Cells were maintained in culture medium (DMEM/HamsF12 supplemented with 10% fetal calf serum (FCS), glutamine (2 mmol/l) and antibiotics (penicillin/streptomycin/gentamycin)).

Generation of TiBc cultures from primary tumors

Tumor fragments were cut into small pieces and homogenized. Cell suspensions were obtained following nylon passage. Either a total of 5×106 cells were cultured in a cell culture flask or cells were distributed in one 48-well plate in the presence or absence of EBV-containing supernatant of B95/8 cells. To prevent T and NK cell growth, cyclosporin A (5.5×10−7 M) was added. Typically, outgrowth of TiBc cultures was observed after a period of 4–8 weeks. Established TiBc were harvested, expanded and further characterized. All cell culture reagents were obtained from PAA (Cölbe, Germany), antibiotics and antifungal agents were from the pharmacy of the university hospital Rostock.

Clonality analysis of TiBc

Genomic DNA was extracted from pelleted TiBc cultures with the Qiagen extraction kit (Hilden, Germany). Clonality was tested using the BIOMED-2 multiplex PCRs protocols to detect Ig gene rearrangements with Genescan detection [17]. Denatured PCR products are size separated in a denaturing capillary sequencing polymer and detected via automated scanning with a laser. Monoclonal cell samples will give rise to PCR products of identical size (single peak), whereas in polyclonal samples many different IGH PCR products will be formed, which show a characteristic Gaussian size distribution.

Histological and immunohistochemical assessment of TiBc

Peritumoral lymphocytic infiltration patterns were assessed by routine H&E staining. Additionally, representative paraffin-blocks were selected for immunohistochemistry with commercial antibodies directed against CD3, CD20, CD79a, and CD21 using standard protocols.

Flow cytometric phenotyping

Activation and differentiation status of TiBc were traced by flow cytometry using the following FITC-, PE or APC-conjugated Abs: CD3, CD19, CD20, CD23, CD38, CD27, CD80, MHC I (Immunotools, Friesoythe, Germany), CD83, CD138, and MHC II (Miltenyi Biotec, Bergisch-Gladbach, Germany). Samples were analyzed on a FACSCalibur Cytometer (BD-Biosciences, Heidelberg, Germany). Data analysis was performed using CellQuest software (BD-Biosciences).

HIg- and Cell-ELISA

Ig isotype production of TiBc was quantified by ELISAs specific for IgG, IgA, IgM, IgD and IgE (Bethyl Laboratories, Montgomery, TX, USA). Briefly, ELISA plates were coated with anti-human Ig (50 µg/ml; 4°C), washed and blocked. TiBc supernatants (1∶50; collected for a period of six month) were added, bound Ig was detected with horse-radish-peroxidase-conjugated anti-human Ig (1∶50.000), and visualized by 3.3.5.5-Tetramethylbenzidin. Reactions were stopped using 2 M H2SO4. Absorbance was measured on an ELISA plate reader at 450 nm (reference 620 nm). Ig concentrations were determined by comparison with a standard curve generated from serial dilutions of Ig standards.

For Cell-ELISA, 96-well plates, seeded with fixed tumor cells, were used. All washing and blocking steps were done as described. One µg/well IgG was added and incubated at room temperature (2 h). Therapeutic Abs Cetuximab™ (anti-EGFR) and Trastuzumab™ (anti-Her2/neu) served as positive, Rituximab™ (anti-CD20) as negative controls. As a measure for IgG tumor cell binding, extinctions from the background (medium alone, <0.20) were subtracted.

In vitro Binding assays

CRC cell lines (0.5×106) were fixed in 4% formalin for 30 min and incubated with IgG-supernatants from several TiBc cultures (1 µg/ml; 1 h; 4°C). Therapeutic control Abs were applied as described. After washing, cells were stained with secondary anti-human IgG-FITC conjugated Ab (1∶40). Data acquisition was done as described.

Immunofluorescence was performed with fixed tumor cells followed by blocking (2% BSA; 1 h) and incubation with IgG-supernatants from selected TiBc clones (1 µg/ml, 2 h). Afterwards, Alexa 546-conjugated anti-human IgG (1∶100, 1 h) was applied. Cell nuclei were counterstained with DAPI. Tumor cell binding was visualized by fluorescence microscopy (Leica DM 4000 M; Leica Wetzlar, Germany). Pictures were obtained using the provided evaluation software (Leica Image Pro Plus 6.0 image analysis software).

Statistics

Statistical differences were determined by using the two-sided Fisher's exact T-test. The tests were performed with Sigma-Stat 3.0 (Jandel Corporation, San Rafael, CA, USA). The criterion for significance was taken to be p<0.05.

Results

Patterns of lymphocytic infiltration

TiBc were observed to concentrate in the stroma at the invasive margin, and they were never seen between the epithelia of the neoplastic glands (Figure 1A, B). Distribution of TiBc, tumor-infiltrating CD3+ T cells, as well as mature plasma cells was quite heterogeneous, even within a single tumor (Figure 1 C, D). In addition, at the invasive margin follicular aggregates of TiBc residing in a mesh of follicular dendritic cells were seen (Figure 1E, inset), and these varied in frequencies between cases.

thumbnail
Figure 1. Tumor-infiltrating lymphocytes in a primary colorectal carcinoma (HROC60) highlighted by immunohistochemistry.

(A, B) TiBc are observed to concentrate in follicular aggregates at the invasive margin. (C, D) Diffuse T cell infiltration within tumor stroma and to a minor extend within neoplastic glands given by positive staining for CD3. (E) TiBc in follicular aggregates (arrows) reside in a mesh of follicular dendritic cells (inset). Original magnification (A, C, E) 4× and (B, D) 20×.

https://doi.org/10.1371/journal.pone.0032639.g001

Generation of EBV-transformed TiBc cultures

Establishment of TiBc bulk cultures was attempted by EBV transformation for 19 tumors (Table 1). Initially, we generated 14 TiBc bulk cultures (74% success rate) but permanent growth could not be obtained in three cases. However, the remaining 11 cultures proceeded to grow continually. In these, a characteristic in vitro pattern of follicular aggregates was observed – similar to peripheral EBV-transformed B cells. Success in obtaining cultures did not correlate with density or pattern of lymphocytic infiltration of the primaries. Moreover, it was quite independent from the amount of TiBc harvested upon initial isolation (Table 1). However, due to the technical challenge of FACS analysis from primary tumor tissue, those data on CD19+CD20+ B cells in primary CRC need to be interpreted with caution.

To sum up these findings, this method circumvents problems implicated with low B cell numbers obtained by isolation from fresh primary tumors and the technical demands of handling freshly isolated TiBc [11].

TiBc cultures are of clonal origin

Clonality analysis for IGH and IGK gene rearrangement was performed from the 11 TiBc bulk cultures. Comparison of V(D)J rearrangements and junctional mutation patterns revealed monoclonality in each of the established culture. By applying Gene Scanning fragment-length PCR, predominant clonal rearrangement (monoclonality) was identified as a single peak consisting of one type of PCR product (exemplary results are given in Figure S1A). Analysis of early passages of the cultures demonstrates, however, oligoclonal junctional mutation patterns and thus implies that monoclonality is the result of continuous in vitro selection (Figure S1B).

Equally important, demonstration of monoclonality for all of the long-term cultures forms the basis for TiBc characterization and applying Abs produced thereof for functional analysis.

TiBc are of mature immunophenotype

The most interesting result was the high expression of the B cell maturation marker CD23, suggesting growth after antigenic stimulus (Table 2). Consistent with ongoing maturation, in each clone a heterogeneous pattern of B and plasma cell markers was observed (Table 2). Expression of the general activation marker CD83 ranged from zero to 60%. None of the clones expressed T cell markers confirming their B lymphoid origin. Expression of MHC class I and II molecules as well as the co-stimulatory adhesion molecule CD80 was very high.

thumbnail
Table 2. Immunophenotypes of TiBc clones by flow-cytometry and results of Cell ELISAs.

https://doi.org/10.1371/journal.pone.0032639.t002

Ig repertoire produced by TiBc clones

All of the analyzed supernatants contained detectable, though varying levels of either one of the three main Ig isotypes: IgG, IgM or IgA (Table 2). Production of IgD or IgE was not observed in any of the cultures. The pattern of Ig secretion did not alter during the observation period. Importantly, among the 11 cultures that had been included into the analysis, exclusive production of IgG was found in 55% (6/11 cultures).

IgGs specifically bind to tumor cells

Of the five TiBc-derived IgGs included into these analyses, four were observed to bind to HCT116 and three to HROC24 and HROC46 (Table 2) in initial cell ELISA screenings. Of note, the affinities of TiBc-produced IgGs were comparable to or even higher than those of the therapeutic Abs specific for EGFR and Her2/neu. These two Abs were chosen as positive controls due to their high expression on the analyzed cell lines (each 80–100%, Figure 2A).

thumbnail
Figure 2. In vitro binding assay.

(A) Histograms show HCT116 tumor cells following incubation in secondary FITC-conjugated Ab only (black curves), therapeutic Abs (green curves, upper panel) or TiBc-derived IgGs (green curves middle and lower panel). Representative experiments each performed in triplicates are shown. (B) Quantitative analysis for flow cytometric assessment of TiBc-derived IgG binding capacity towards tumor cell targets (HROC24, HROC46, and HCT116). As positive control, fixed cells were stained with therapeutic Abs Cetuximab and Trastuzumab. Negative controls consisted of fixed tumor cells either stained with Rituximab or the secondary FITC-conjugated Ab only.

https://doi.org/10.1371/journal.pone.0032639.g002

Specific allogeneic tumor cell recognition was confirmed for three of the IgGs by flow cytometry (Figure 2B). IgG from TiBcHROC66 and TiBcHROC90 exhibit strong avidity towards all cell lines tested and both bound to >90% of the tumor cells. Likewise, the mean fluorescence intensity, representing the number of bound Ab molecules per cell, differed only marginally between cells (data not shown). TiBcHROC57-derived IgG displayed an intermediate binding affinity with a maximum of 15% staining for HROC46 cells. When analyzing the other IgGs, weak tumor cell binding if any was observed. Less than 5% of tumor cells allowed binding of IgG from TiBcHROC59, 68, and 86 (Figure 2A).

Finally, immunofluorescence studies were done for further confirmation of the above findings and to get an idea of the cellular antigen distribution. Tumor cell recognition was specific, and this was most pronounced for supernatants from TiBcHROC66 and 90. Both IgGs bound to HCT116 cells with high affinity (Figure 3, upper panel). Target cell staining with TiBcHROC57-derived IgG was weaker, but still specific and mostly intracellular (Figure 3, middle panel). Again, negligible staining was shown for TiBcHROC68-derived IgG. Similar observations were made for HROC46 with highest binding for IgG from TiBcHROC66 and TiBcHROC90. TiBcHROC57-derived IgG bound tumor cells to a lesser extent. Positive staining was shown for some, but not all tumor cells (Figure 3, lower panel).

thumbnail
Figure 3. Representative immunofluorescence images of tumor cells showing positive binding of both membranous as well as intracellular target structures by TiBc-derived IgGs.

(A) HCT116 and (B) HROC46 tumor cells were stained with TiBc-derived IgGs and Alexa 546-conjugated anti-human IgG. Cell nuclei were counterstained with DAPI. Therapeutic antibodies Cetuximab and Rituximab served as positive and negative control, respectively. Original magnification ×40.

https://doi.org/10.1371/journal.pone.0032639.g003

No evidence for latent EBV-transformation in vivo

Growth of lymphoblastoid tumors occasionally complicates xeno-transplantation of tumors in mice [18]. This gave rise to the hypothesis that (some) TiBc could be latently infected by EBV and hide in the immunosuppressive environment of human CRCs to escape EBV-specific T cells [18].

Our in vitro system provided a perfect basis to test this hypothesis. TiBc cultures from another 12 CRC were cultured in the presence or absence of EBV (Table 3). There was no outgrowth in any of the cultures without exogenous EBV, whereas with EBV, a total of 97 TiBc clones was obtained from 10/12 cases. Additionally, this simple procedure facilitates the generation of several TiBc clones from one tumor specimen.

thumbnail
Table 3. Data of colorectal carcinomas used for generation of TiBc cultures with and without EBV, percentage of CD19+CD20+ B cells from primary tumors (flow cytometry), and outcomes.

https://doi.org/10.1371/journal.pone.0032639.t003

Discussion

In various human cancers, CRC among them, the degree of lymphocytic tumor infiltration correlates with patients' clinical course. Previous studies largely focussed on T cells [5], [6]. Besides, a few preliminary studies described the positive impact on systemic humoral immune responses not only for early detection but also for cancer immunotherapy [19], [20]. We here began to elucidate the role of the humoral anti-tumor immune response within the tumor microenvironment. First, by EBV-transformation we were able to generate long-term monoclonal B-cell lines from TiBc. This procedure was comparatively easy to carry out and quite efficient, yielding 11 lines from 19 CRC specimens. We wish to point out, that this protocol, backed up by proof of monoclonality by the BIOMED protocols used in the diagnostics of lymphomas, offers itself as a basis to start from for any researchers working in this field. It circumvents efficiently the problems implicated in handling fresh TiBc isolates that often are very low in numbers.

The mature immunophenotype of TiBc from primary CRC observed in this study suggests activation and antigen-induced maturation, making accidental tumor tissue infiltration quite unlikely. In agreement with these observations, B cells infiltrating human breast carcinoma tissues were shown to undergo antigen-driven proliferation, somatic hypermutation and affinity maturation, thus representing a tumor specific humoral immune response [11]. This interpretation is further supported by the fact that, as seen by immunohistochemistry, in CRC the great majority of TiBc resides in follicular aggregates. Likewise, peritumoral follicular aggregates of lymphocytes have long ago been reported as “Crohn's like reaction”. This positive prognosticator for CRC was interpreted as an immune-mediated anti-tumor effect [21], [22].

Most of the TiBc cultures started to produce IgG directly after cultivation, IgA secretion was found in one case. Beside IgG, IgA is known to be the other main isotype, secreted exclusively by B cells following a specific stimulus, and this provides a further argument for our hypothesis that B cell infiltration into the tumors is not accidental. Unraveling the functional capacity of this IgA will be of great interest, however in this work we focused on IgG-secreting TiBc cultures. IgG is generally considered to have the greatest potential for therapeutic purposes, because it is most efficient in mediating complement- or NK cell-mediated tumor cell lysis, and has an extended plasma half life [23][26].

Using functional assays, specific binding to tumor cells was demonstrated especially for two of the IgGs (from TiBc66 and TiBc90). Both intra- and extracellular antigens were recognized and since all binding experiments were performed in allogeneic settings, these antigens must be shared between different tumor cells. These findings are in line with and add to reports on TSA by other groups [11], [12], [27]. Investigations to identify the antigens bound by TiBc-derived IgGs at the molecular level are on their way, and we are confident that this will help to understand the process of CRC immunoediting [28].

High expression of MHC class I and II molecules as well as the co-stimulatory adhesion molecule CD80 is another interesting finding in this study. This suggests a role for TiBc not only as producers of tumor-specific Abs but also as local APCs, potentially modulating T cell restricted immune responses. One might speculate that tumor-antigen specific TiBc constitute highly efficient APC especially when compared with antigen-unexperienced circulating B cells. However, recruitment of TSA-specific B cells (namely regulatory B cells) by tumor cells in order to suppress antitumoral T cells in situ is also imaginable [29].

Finally, it was reported that EBV might induce transient production of low-affinity, unstable IgM [30]. Since isotype switch during long-term culture was not observed in any of the TiBc cultures, we consider it most likely that our cases of TiBc IgM production (n = 4) are a primary antigen-driven immune response and not induced by EBV transformation. It will be of interest to analyze, if stimulation of the IgM-producing TiBc with autologous T helper cells will induce Ig class switching, possibly leading to the production of highly affine IgG. Secondly, since tumor-specific IgM antibodies have been described, specific recognition of tumor structures may be anticipated [31][33].

The major findings of our study may be summarized as follows: (a) human CRCs harbor B cells (i.e. TiBc) that can be long-term cultured subsequent to EBV-immortalization; (b) TiBc harvested from these are antigen-experienced and secrete Ig of the three main Ig isotypes (IgG, IgA, IgM) in amounts sufficient for functional studies; (c) IgG derived from several TiBc clones strongly bind to antigenic structures present on several allogeneic tumor cell lines; and (d) TiBc show no evidence for latent EBV-infection in vivo.

On the basis of these novel findings, Ig-producing long-term TiBc cultures may provide a convenient cellular tool for the identification of novel or relevant TSA.

Supporting Information

Figure S1.

Clonality analysis using the BIOMED-2 multiplex PCRs protocols to detect Ig gene rearrangements with Genescan detection. (A) IGH and IGK gene rearrangement from selected TiBc cultures giving rise to PCR products of identical size (single peak). This confirms monoclonality of TiBc cultures. Monoclonal B-LCLs were taken as control. (B) Exemplary data for early passage TiBcHROC68 culture. Oligoclonality was detected by different PCR products indicating the presence of several subclones at early culture.

https://doi.org/10.1371/journal.pone.0032639.s001

(TIF)

Acknowledgments

The authors kindly thank Mathias Krohn for his excellent technical assistance and Christina S. Mullins for carefully proofreading the manuscript.

Author Contributions

Conceived and designed the experiments: AJ ML. Performed the experiments: CM AJ CO FP. Analyzed the data: CM AJ ML. Contributed reagents/materials/analysis tools: ML EK. Wrote the paper: CM AJ ML FP.

References

  1. 1. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, et al. (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654–66.
  2. 2. Fridman WH, Galon J, Pagès F, Tartour E, Sautès-Fridman C, et al. (2011) Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 71: 5601–5.
  3. 3. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, et al. (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29: 610–8.
  4. 4. Coronella-Wood JA, Hersh EM (2003) Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 52: 715–738.
  5. 5. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, et al. (1998) CD8+ T cells infiltrated within cancer cell nests as a prognosic factor in human colorectal cancer. Cancer Res 58: 3491–3494.
  6. 6. Prall F, Dührkop T, Weirich V, Ostwald C, Lenz P, et al. (2004) Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 35: 808–816.
  7. 7. Nelson BH (2010) CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 185: 4977–4982. Review.
  8. 8. Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, et al. (2002) Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 169: 1829–36.
  9. 9. Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L, et al. (1992) Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res 12: 1463–6.
  10. 10. Nzula S, Going JJ, Stott DI (2003) Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 63: 3275–80.
  11. 11. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, et al. (2011) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. Jun 14.
  12. 12. Hansen MH, Nielsen HV, Ditzel HJ (2002) Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells. J Immunol 169: 2701–2711.
  13. 13. Yasuda M, Takenoyama M, Obata Y, Sugaya M, So T, et al. (2002) Tumor-infiltrating B lymphocytes as a potential source of identifying tumor antigen in human lung cancer. Cancer Res 62: 1751–1756.
  14. 14. Rosén A, Gergely P, Jondal M, Klein G, Britton S (1977) Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro. Nature 267: 52–54.
  15. 15. Ostwald C, Linnebacher M, Weirich V, Prall F (2009) Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. Int J Oncol 35: 321–327.
  16. 16. Linnebacher M, Maletzki C, Ostwald C, Klier U, Krohn M, et al. (2010) Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer 10: 362.
  17. 17. van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, et al. (2003) Design and Standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17: 2257–2317.
  18. 18. Fujii E, Suzuki M, Matsubara K, Watanabe M, Chen YJ, et al. (2008) Establishment and characterization of in vivo human tumor models in the NOD/SCID/gamma(c)(null) mouse. Pathol Int 58: 559–67.
  19. 19. Kanojia D, Garg M, Gupta S, Gupta A, Suri A (2011) Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Am J Pathol 178: 1009–20.
  20. 20. Silk AW, Schoen RE, Potter DM, Finn OJ (2009) Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol Immunol 47: 52–6.
  21. 21. Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, et al. (2009) Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 15: 6412–20.
  22. 22. Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, et al. (2010) Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol 11: 19.
  23. 23. Greiner JW, Guadagni F, Hand PH, Pestka S, Noguchi P, et al. (1990) Augmentation of tumor antigen expression by recombinant human interferons: enhanced targeting of monoclonal antibodies to carcinomas. Cancer Treat Res 1990 51: 413–32.
  24. 24. Wallace PK, Howell AL, Fanger MW (1994) Role of Fc gamma receptors in cancer and infectious disease. J Leukoc Biol 55: 816–26.
  25. 25. Dechant M, Valerius T (2001) IgA antibodies for cancer therapy. Crit Rev Oncol Hematol 39: 69–77.
  26. 26. Jefferis R (2007) Antibody therapeutics: isotype and glycoform selection. 2007. Expert Opin Biol Ther 7: 1401–13.
  27. 27. Zhang H, Lake DF, Barbuto JA, Bernstein RM, Grimes WJ, et al. (1995) A human monoclonal antimelanoma single-chain Fv antibody derived from tumor-infiltrating lymphocytes. Cancer Res 55: 3584–3591.
  28. 28. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565–70.
  29. 29. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, et al. (2011) Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T regulatory cells. Cancer Res 71: 3505–15.
  30. 30. Fraussen J, Vrolix K, Martinez-Martinez P, Losen M, Meulemans E, et al. (2010) A novel method for making human monoclonal antibodies. J Autoimmun 35: 130–134.
  31. 31. Brändlein S, Vollmers HP (2004) Natural IgM antibodies, the ignored weapons in tumour immunity. Histol Histopathol 19: 897–905.
  32. 32. Domschke C, Schuetz F, Ge Y, Seibel T, Falk C, et al. (2009) Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res 69: 8420–8.
  33. 33. Vollmers HP, Braendlein S (2005) The “early birds”: natural IgM antibodies and immune surveillance. Histol Histopathol 20: 927–937.